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BACKGROUND: To define the spectrum of human papillomavirus (HPV) types and establish an age limit for triage HPV testing in atypical
squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL).
MATERIALS AND METHODS: 343 liquid-based cytological samples from the population-based screening programme with minor
abnormalities were subjected to HPV genotyping (Linear Array, Roche, Basel, Switzerland).
RESULTS: High-risk human papillomavirus (HR-HPV) was found in 71% of LSIL and 49% of ASCUS cases (Po0.001). High-risk human
papillomavirus prevalence was age-dependent in LSIL (P¼0.01), with decreasing prevalence until the age of 50 years, followed by a
slight increase. Human papillomavirus type 16 was the most common HR-HPV, found in 23% of HPV-positive women. Human
papillomavirus type 18 was the sixth most common, found in 9.9% (Po0.001). An age-dependent quadratic trend was observed for
multiple infections (P¼0.01) with a trough at about 42 years. The most common HR-HPV types to show a coinfection with HPV16
(clade 9) were HPV39 (28%), 45 (38%), and 59 (46%), belonging to HPV18 clade 7. The frequency of low-risk (LR) vs probable HR
and HR-HPV also followed an age-dependent quadratic trend.
CONCLUSIONS: After the age of 25 years, HR-HPV prevalence is similar in LSIL and ASCUS cases, motivating a low age limit for triage
HPV testing. Multiple infections and LR/HR-HPV dominance are age-dependent. Genotyping in longitudinal design is needed to
elucidate the importance of multiple infections in cancer progression and in cross-protection from vaccination.
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Persistent infection with high-risk human papillomavirus (HR-HPV)
types has a critical aetiological function in the development
of cervical intraepithelial neoplasia (CIN) and cervical cancer
(Walboomers et al, 1999). Progression from low-grade to high-
grade dysplasia and invasive disease is rare in the absence of
HPV (Khan et al, 2005). Human papillomavirus types16 and 18 are
incriminated as the causative agents in 65–77% of cervical cancers
(Smith et al, 2007). The effect of multiple HPV infections on CIN
and cancer development is still unclear, but several publications
argue that certain multiple infections may confer a risk similar to
the risk of a single HPV16 infection (Becker et al, 1994; Trottier
et al, 2006; Wheeler et al, 2006). With the implementation of
vaccination programmes, interest is also growing in cross-
protection against HPV genotypes belonging to the same clade
or phylogenetic species (Ault, 2007; Castellsague et al, 2008;
Poolman et al, 2008; Sargent et al, 2008). Human papillomavirus
type 16 belongs to clade 9, as do HPV31, 33, 35, 52, and 58, whereas
HPV18 belongs to clade 7, along with HPV39, 45, 59, and 68
(de Villiers et al, 2004).
Awareness of the causal relationship between HPV infection and
cervical cancer has made the detection of the virus an attractive
approach to identify women at risk of developing cervical cancer
(Cuzick et al, 2008). This approach, which is particularly
important in cases of minor cytological abnormalities, is
internationally accepted for use in cases of atypical squamous
cells of undetermined significance (ASCUS). However, it has not
been generally recommended in cases of low-grade squamous
intraepithelial lesions (LSILs) because of the high prevalence of
oncogenic HPV in this group (Sherman et al, 2002; Schiffman and
Solomon, 2003; Arbyn et al, 2006; Wright et al, 2007). Women with
minor cytological abnormalities account for a large proportion of
those referred for further investigation, a process resulting in
psychological stress and considerable health-care costs (Freeman-
Wang et al, 2001; Idestrom et al, 2003).
In Sweden, about 3–5% of all smears show some kind of
abnormality, almost 80% of which are minor cytological changes
(Sparen, 2008). Current Swedish guidelines for management of
minor abnormalities do not include HPV testing; rather, a second
Pap smear or colposcopy is required (Ahlberg-Ranje et al, 2008).
The question whether HPV testing may improve the Swedish
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sscreening programme is under discussion, especially in the light of
the potential to identify precancerous lesions among ASCUS and
LSIL and to distinguish these from reactive or degenerative lesions.
According to our previous study, complementing liquid-based
cytology (LBC) with an HPV test in cases of ASCUS and LSIL may
lead to a 40% decrease in the number of these women referred for
further investigation (Froberg et al, 2008). Human papillomavirus
prevalence is high among younger women with LSIL, which is why
an age limit for triage HPV testing is being sought. We wished to
compare the age-specific prevalence of HR-HPV in these
cytological categories to show that difference in prevalence is not
an argument against triage testing.
The purpose of our study was to identify the HPV types
present among women with minor cytological abnormalities
using the PCR-based Linear Array HPV Genotyping Test (Roche
Diagnostics, Basel, Switzerland) and to describe the prevalence of
multiple infections in relation to age before the implementation of
vaccination programmes.
MATERIALS AND METHODS
Patients
From September 2005 through to September 2006, 4204 LBC
samples from a population-based screening programme were
obtained from seven maternity health centres in Southern Stock-
holm as previously reported (Froberg et al, 2008). Later in 2006, an
additional 2024 samples were collected. Minor cytological
abnormalities were found in 343 (5.5%) of these 6228 LBC
samples, comprising the cytological classifications of ASCUS and
LSIL based on the Bethesda nomenclature system (Solomon et al,
2002). According to Swedish recommendations, koilocytosis with-
out signs of dysplasia was reported as non-pathologic. Therefore,
the LSIL group only contains samples corresponding to cytological
cervical intraepithelial neoplasia grade 1 (CIN1). Approval from
the ethics committee and written informed consent from all
women were obtained before inclusion.
HPV DNA extraction and detection with linear array
A 2ml PreservCyt suspension from the remaining LBC sample
after cytological evaluation was centrifuged and the cell pellet was
lysed according to instructions in the Total Nucleic Acid Isolation
kit. DNA was extracted using the MagNA Pure LC robot and
analysed with the Linear Array HPV Genotyping Test (LA),
according to the manufacturer’s instructions (all procedures by
Roche). The method includes a PCR amplification of extracted
HPV DNA using a pool of biotinylated primers that hybridise in
the L1 region of the HPV genome, chemical denaturation of HPV
DNA amplicons to single-stranded DNA, followed by hybridisation
with matching type-specific DNA probes immobilised on nylon
strips, and detection by colorimetric determination. The result is a
pattern of blue lines on a nylon strip, which is visually read by
comparing the pattern with a reference guide. The LA test covers
37 HPV types including 12 HR-HPV types (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59), 6 probable high-risk (pHR-) HPV types (26, 53,
66, 68, 73, 82), and 19 low-risk or undetermined-risk (LR-) HPV
types (6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84,
IS39, CP6108) (Munoz et al, 2003).
Statistical analysis
Data were analysed with the software STATISTICA 6.1 (Statsoft
Inc, Tulsa, OK, USA). Pearson’s w
2 and Yates corrected w
2 (for
no5) tests were used to compare proportions, and Student’s t-test
was used to compare continuous variables between two groups.
After plotting proportions of HR-HPV- and HPV-infected women
and multiple infections, respectively, in each age group, a linear or
polynomial fit was visually assessed to be the best model for
logistic regression. We tested whether the proportion in each age
group decreased linearly with age (log(p/1 p)¼b0 b1x) and
whether this was significantly different from null. Then we added a
second degree (log(p/1 p)¼b0 b1xþb2x
2) to test whether the
increase in women over a certain age was significantly different
from null. We controlled for covariation between age and age
2
using centred age and centred age
2 in the model. The larger model
with a second degree provided a better explanation as tested
with Nagelkerke R
2. Therefore, we concluded that the quadratic
function, log(p/1 p)¼b0 b1xþb2x
2, could best describe the
relationship between prevalence of HR-HPV in LSIL cases and
age, multiple infections and age, and HR/LR-HPV dominance and
age. Logistic regressions were also carried out using age group and
cytological diagnosis as categorical predictors, as well as HPV
prevalence as the dependent variable. The null hypothesis of no
difference was rejected at a significance level of Po0.05.
RESULTS
Cytology results and age distribution
There were 223 cases of LSIL and 120 cases of ASCUS, including
three cases of atypical glandular cells of undetermined significance
(AGUS). Age was illegible on one LSIL sample and on one ASCUS
sample; therefore age was recorded in 341 of 343 women. The
mean age was 33.6 years (median 32, range 22–60). Women were
grouped according to age at 5-year intervals from age 20–49 years,
whereas the oldest women, aged 50–60 years, were placed into a
single comparably sized group. Table 1 shows age distribution. The
mean age of women with ASCUS was 35.7 years and of those with
LSIL was 32.4 years (P¼0.002). In all, 73% of the women were
younger than 40 years. Women with ASCUS were older than
women with LSIL; 38% of women with ASCUS were 40 years or
older, compared with 21% of women with LSIL (Po0.001, w
2).
HPV prevalence
The b-globin gene from all 343 samples was successfully amplified
as shown by the presence of both low- and high-concentration
bands on the array. A total of 282 (82%) women tested positive for
one or more of the 37 included HPV types. Human papillomavirus
prevalence ranged from 92% in the 20–29-year age group to 62%
in women aged 40–45 years. Prevalence was 67% in women over
50 years. Age-specific prevalence for all HPV types and HR-HPV
types (12 or 13 types) was higher in younger age groups and there
was a linear decline with age (Po0.001, logistic regression,
Table 1).
Human papillomavirus was more common in women with LSIL
(207 out of 223, 93%) than in women with ASCUS (75 out of 120,
63%, Po0.001, w
2). Age-specific prevalence of all HPV types in
women with ASCUS compared with women with LSIL is shown in
Figure 1. Human papillomavirus prevalence was significantly
dependent on age group (P¼0.03), but did not reach a statistically
significant difference between ASCUS and LSIL within each age
group using logistic regression (P¼0.098). However, there is
an apparent tendency for increasing discrepancy with lower and
especially higher age. w
2-tests to compare proportions gave
significant differences in all age groups, except in the 30–39 year
age group.
High-risk or pHR-HPV (18 types) was found in 68 (57%) ASCUS
cases, compared with 181 (81%) LSIL cases (Po0.001, w
2). High-
risk human papillomavirus (12 types) was found in 59 (49%) cases
among women with ASCUS, compared with 158 (71%) in women
with LSIL (Po0.001, w
2). Considering 13 types (HR-HPV and pHR-
HPV 68), these were found in 60 (50%) ASCUS cases and in 159
(71%) LSIL cases (Po0.001, w
2). Figure 1 shows that HR-HPV
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sprevalence was age dependent among women with LSIL (P¼0.001,
logistic regression), with a decreasing prevalence until the age of
50 years. A small increase was found in older women, but this was
not statistically significant (P¼0.19 for age
2). A linear correlation
between HR-HPV prevalence and age (but not age group) was also
found in ASCUS cases (Figure 1). Age-specific HR-HPV prevalence
did not reach a statistically significant difference between ASCUS
and LSIL using logistic regression (P¼0.15). w
2-tests revealed a
significant difference in HR-HPV prevalence between ASCUS and
LSIL in the youngest age group (Table 1).
HPV genotype distribution
Figure 2 shows the prevalence of HR-HPV genotypes (including
pHR-HPV68) in each age group in all women. Human papilloma-
virus type 16 was the most common HR-HPV and was found in 65
(23%) of the HPV-positive women, ranging from 30% (20 out of
67) in women aged 25–29 years to 14% (3 out of 22) in women
aged 45–49 years (P¼0.22, w
2). Remarkably, HPV18 was only
found in 28 (9.9%) of all HPV-positive women (Po0.001 com-
pared with HPV16, w
2). Human papillomavirus types 51, 52, 56,
and 31 were also more common than HPV18. Human papilloma-
virus type 51 was equally or more common than HPV16 among
Table 1 Age-specific HR-HPV and multiple HR-HPV prevalence in the study population
Total number of women HR-HPV HR-HPV and HPV68 Multiple HR-HPV
Cytology Cytology Cytology Cytology
Age group
(years) ASCUS LSIL
ASCUS
No. (%)
a
LSIL
N (%)
a P (v
2)
ASCUS
No. (%)
a
LSIL
No. (%)
a P (v
2)
ASCUS
No. (%)
b
LSIL
No. (%)
b P (v
2)
20–24 18 55 8 (44) 47 (85) o0.001 9 (50) 48 (87) o0.001 5 (63) 23 (49) 0.74
25–29 23 50 15 (65) 40 (80) 0.17 15 (65) 40 (78) 0.17 7 (47) 18 (45) 0.91
30–34 17 35 10 (59) 22 (63) 0.78 10 (59) 22 (63) 0.78 4 (40) 9 (41) 0.73
35–39 16 36 10 (63) 23 (64) 0.92 10 (63) 23 (64) 0.92 2 (20) 8 (35) 0.66
40–44 21 18 6 (29) 10 (56) 0.09 6 (29) 10 (56) 0.09 0 (0) 3 (30) 0.41
45–49 13 15 7 (54) 7 (47) 0.70 7 (54) 7 (47) 0.70 2 (29) 1 (14) 1.0
50–60 11 13 3 (27) 8 (62) 0.20 3 (27) 8 (62) 0.20 2 (67) 1 (13) 0.30
All
c 119 222 59 (49) 158 (71) o0.001 60 (50) 159 (71) o0.001 22 (38) 63 (40) 0.70
ASCUS¼atypical squamous cells of undetermined significance; HR-HPV¼high-risk human papillomavirus; LSIL¼low-grade squamous intraepithelial lesion.
aPercentage of total
number of women in the age group.
bPercentage of HR-HPV positive women in the age group.
cTwo women are missing; one ASCUS case with HPV42 and one LSIL case with
HPV52.
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Figure 1 Age-specific prevalence of human papillomavirus (HPV)
(all types) and HR-HPV infection in women with ASCUS and LSIL.
Human papillomavirus all types P(age group cytological diagnosis)¼0.10;
LSIL P(age)¼0.20, P(age group)¼0.03, P(age
2)¼0.003; ASCUS
P(age)¼0.001, P(age group)¼0.04, P(age
2)¼0.34; HR-HPV P(age group-
cytological diagnosis)¼0.15; LSIL P(age)¼0.001, P(age group)¼0.01,
P(age
2)¼0.19; ASCUS P(age)¼0.04, P(age group)¼0.11, P(age
2)¼0.16;
all P-values calculated by logistic regression.
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Figure 2 Age-specific distribution of the HR-HPV genotypes including
pHR-HPV68 in all women. The total exceeds 100%, as many women carry
more than one HPV genotype.
Age-specific prevalence of HPV in ASCUS and LSIL
S Brismar-Wendel et al
513
British Journal of Cancer (2009) 101(3), 511–517 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swomen over 45 years of age. Among women with ASCUS, the most
prevalent HR-HPV genotype was HPV16 (16%), followed by
HPV51 and 52 (10%). Among women with LSIL, HPV16 was detec-
ted in 21%, followed by HPV56 in 11% of women (Figure 3).
Table 2 outlines women infected with HPV16, 18, clade 9 HPV
types, and clade 7 HPV types to elucidate the preventive potential
of current HPV vaccines against low-grade cytological abnormal-
ities. As shown in Figure 4, we found a shift in predominant geno-
types with age. The proportion of LR genotypes increased with age,
following a quadratic function (Po0.001, logistic regression).
Multiple infections
Multiple infections were common in our material (Figure 5). On
average, we found 2.5 genotypes per HPV-positive sample. In one
LSIL sample, nine different genotypes were found. In all, 54% (185
out of 343) of all women carried more than one HPV type. Women
with LSIL had multiple types (61%, 136 out of 223) more
frequently than did women with ASCUS (41%, 49 out of 120,
Po0.001, w
2). Taking only HPV-positive samples into account,
multiple infections were equally common in women with ASCUS
and LSIL (65% or 49 out of 75, and 66% or 136 out of 207,
respectively). The age-specific prevalence of multiple infections
followed a quadratic function in LSIL cases (P¼0.001, logistic
regression, Figure 5). This was also found in multiple HR-HPV
infections among the HR-HPV-positive LSIL cases (P¼0.04,
logistic regression). Among HR-HPV-positive samples, 39% (85
out of 217) were infected by more than one HR-HPV type and
similar results were found for LSIL and ASCUS samples (39.9 and
37.3%, respectively, P¼0.73, w
2).
In all, there were 710 individual HPV infections. Coinfection was
equally common among LR-HPV genotypes (243 out of 268, 92%)
and pHR-HPV genotypes (87 out of 101, 91%, P¼0.21, w
2).
Individuals infected with HR-HPV genotypes were somewhat less
likely to be coinfected with a second HPV type (283 out of 341,
83%, P¼0.006, w
2). The high-risk types that were most commonly
seen in coinfection with HPV16 (clade 9) were HPV39 (28%), 45
P=0.02
P=0.46
P=0.28
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Figure 3 Prevalence of the most common HR-HPV (including pHR-
HPV68) genotypes in all LSIL and ASCUS cases.
Table 2 Preventive potential of current HPV vaccines in Stockholm
County, LSIL and ASCUS
Diagnostic group
All ASCUS LSIL
HPV types
No. (%)
(n¼343)
No. (%)
(n¼120)
No. (%)
(n¼223) P
HPV+ (any type) 282 (82) 75 (63) 207 (93) o0.001
HR-HPV+ 217 (63) 59 (49) 158 (70) o0.001
HPV16+ 65 (19) 19 (16) 46 (21) 0.28
HPV18+ 28 (8) 8 (7) 20 (9) 0.46
HPV16/18+ 89 (26) 26 (22) 63 (28) 0.18
Clade 9+ 154 (45) 44 (37) 110 (49) 0.02
Clade 7+ 108 (31) 31 (26) 77 (35) 0.10
Clade 7/9+ 206 (60) 58 (48) 148 (66) 0.001
ASCUS¼atypical squamous cells of undetermined significance; HPV¼human
papillomavirus; LSIL¼low-grade squamous intraepithelial lesion. P-values indicate
differences between ASCUS and LSIL cases. Clade 7: HPV18, 39, 45, 59, 68, 70.
Clade 9: HPV16, 31, 33, 35, 52, 58, 67.
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Figure 4 Age-dependent shift in LR vs pHRþHR frequency (% of all
HPV infections). LR and pHRþHR P(age
2)o0.001 (logistic regression).
LR¼low-risk HPV, pHR¼probable high-risk HPV, and HR¼high-risk
HPV.
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Figure 5 Age-specific prevalence of multiple infections. Multiple HPV
P(age group)¼0.08, P(cytological diagnosis)¼0.63, P(age group cytolo-
gical diagnosis)¼0.73, LSIL P(age
2)¼0.001, turning point 41.6 years,
ASCUS P(age
2)¼0.76. Multiple HR-HPV P(age group)¼0.04, P(cyto-
logical diagnosis)¼0.71, P(age group cytological diagnosis)¼0.24, LSIL
P(age
2)¼0.04, turning point 38.6 years, ASCUS P(age group)¼0.27,
P(age
2)¼0.34. All P-values calculated by logistic regression.
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s(38%), and 59 (46%), belonging to HPV18 clade 7. Interestingly,
HPV18 did not occur in either HPV39 or HPV45 (Pp0.01, w
2), but
was found in 13% of HPV59 infections (all clade 7). The high-risk
types most commonly seen in coinfection with HPV18 were
HPV56 (17%), 33 (14%), and 51 (14%), which did not differ from
frequencies of HPV16 coinfection (P40.7, w
2, for all). Figure 6
displays coinfection between HPV16 or HPV18 and the largest
clades. HPV16-infected women were more often coinfected with
clade 7 types (38%) than with similar clade 9 types (23%), although
this did not reach statistical significance (P¼0.06, w
2). Human
papillomavirus type 18-infected women carried genotypes from
clade 9 in 43% of cases, compared with similar clade 7 genotypes in
11% (P¼0.02, w
2).
DISCUSSION
We have presented an overview of HPV genotypes encountered
in unselected ASCUS and LSIL cases of all ages detected in
a population-based cytology screening programme and then
established the prevalence of multiple infections in these cases.
We found that HPV prevalence varied with age and there was a
slight but non-significant increase in HPV prevalence in women
over 45 years. Others have found similar age-related patterns and
attributed this slight increase to menopausal hormonal and
immunological changes that may facilitate HPV DNA detection
or reactivate latent infections from exposures earlier in life
(reviewed by Bosch et al (2008)). Such findings may also be
related to sexual behaviour and thus to increased exposure, as
many women in this age group have divorced and remarried
(Stevenson and Wolfers, 2007). Our finding of an increasing
proportion of low-risk types in post-menopausal women was also
observed by Castle et al (2006). This observation, including the
increase in multiple infections among women over 50 years, might
also reflect changes in hormonal or immunological status
occurring at menopause. Some evidence suggests a hormonal
effect on oncogene expression, at least for HPV16 and 18, by action
on progesterone/glucocorticoid-responsive elements in the long
control region of the HPV genome (Cole and Danos, 1987; Gloss
et al, 1989). However, more recent research has called such a
mechanism into question (Ruutu et al, 2006), and would instead
suggest hormonal effects impairing apoptosis of infected cells. Oral
contraceptives and high parity are known risk factors for cervical
cancer (Munoz et al, 2002). One common characteristic of these
factors and menopause is a state of anovulation. To our knowl-
edge, no studies have explored whether other ovulatory hormones
such as gonadotropins, inhibin, or prostaglandins could influence
HPV-induced carcinogenesis.
The average prevalence of HR-HPV was higher in LSIL (71%)
than in ASCUS cases (49%), which is consistent with a previous
meta-analysis (Arbyn et al, 2005). However, the LSIL cases had a
significantly lower rate of HR-HPV than the rate reported by the
ASCUS-LSIL-Triage-Study (ALTS) Group (82.9%) (ALTS, 2000).
The ALTS group concluded that triage HPV testing of LSIL had
limited potential for clinical decision making. The difference in
HR-HPV prevalence might be due to different criteria for defining
ASCUS and LSIL, and also to a difference in the mean age of the
populations (24.9 years in ALTS and 33.6 years in this study). We
used the LA assay covering 37 HPV types and defined 12 HPV
types as high risk. ALTS used Hybrid Capture II to define the same
12 HR-HPV types and HPV68 as high risk. This approach should
not introduce any major difference, as HPV68 without coinfection
with another HR-HPV was found only in one case of ASCUS and in
one case of LSIL in our material. Age-dependent HPV prevalence
in women without cytological abnormalities is a known pheno-
menon (Castle et al, 2006; de Sanjose et al, 2007; Bosch et al, 2008).
Age-dependent prevalence in LSIL has been observed and
discussed by Ronco et al (2007), although they only compared
women who were older or younger than 35 years. High-risk human
papillomavirus prevalence was age-dependent in our LSIL cases,
but more stable in ASCUS cases. When using 5-year intervals for
age grouping, the only significant difference in HR-HPV pre-
valence between ASCUS and LSIL was found within the youngest
(20–24 years) age group. In LSIL, the largest drop in HR-HPV
prevalence was after the age of 30 years (83% in women o30 vs
60% in women X30, Po0.001). These findings suggest that age 30,
or even younger, is a suitable cutoff point for HR-HPV triage in
LSIL, when consideration is given only to the prevalence argument.
This is supported by a histological follow-up study of 112 of these
cases by our group, in which 48% of women over 30 years with
LSIL and 60% of women with ASCUS were HR-HPV negative and
none of these had a histology result of CIN2þ (Froberg et al,
2008) and could therefore have avoided additional investigation.
This implies that the number of follow-ups after low-grade or
ambiguous cytology results could be cut in half, at least in women
over 30 years of age. In Figure 7, we present a suggested flowchart
for triage HPV testing.
Viral persistence is believed to be the most important risk factor
for cervical cancer. Yet, this is true only for certain oncogenic types
(Schiffman et al, 2005). Assessment of viral persistence requires
HPV genotyping. Genotyping will also be necessary to monitor the
effects of vaccination and to explore the importance of multiple
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Figure 7 Suggested flowchart for triage HPV testing.
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sinfections. One of the most noteworthy findings in our study was
the high frequency of multiple infections. Similar results were
previously reported by Cuschieri et al (2004) in a general screening
population from Edinburgh using a linear array assay capable of
identifying 27 types and similar liquid-based sampling. We found
that the prevalence of multiple infections was consistent with a
quadratic function, with increasing prevalence among women over
the age of 50 years. One may speculate whether this finding is
caused by re-infection, triggering of a latent infection, or if
detection is favoured by menopausal changes in the epithelium as
mentioned above. Epidemiological cancer data from Statistics
Sweden (SCB) reveal a second peak in cervical cancer incidence in
the 65–69-year age group, which also suggests increased suscept-
ibility in postmenopausal women. Multiple infection increases the
probability of finding at least one carcinogenic type. It is still
unclear whether coinfections with certain types can exert a
synergistic effect on malignant transformation. Microdissection
studies have suggested a polyclonal origin for squamous cervical
cancer (Guo et al, 2001). The importance of multiple infections
needs to be elucidated in longitudinal studies with histological
confirmation of progressive CIN.
The observed elevated specific coinfection rates of HPV16 with
certain other HPV types, such as HPV39, 45, and 59, may be
because of differences in susceptibility to certain genotypes (all
clade 7), as postulated by Liaw et al (2001). We found that HPV18-
infected women were more likely to be coinfected with non-related
clade 9 types than with similar clade 7 types, arguing against
specific susceptibility. Rather, our data support cross-protection
from infection with HPV from the same clade. Up to 60% of
women with minor cytological abnormalities would potentially
benefit from catch-up vaccination, provided full cross-protection
can be assumed, as discussed by Castellsague et al (2008).
As far as we know, our study is the only one to describe the
prevalence of HPV genotypes in ASCUS and LSIL cases among
women of all ages in Sweden. The relative frequencies of individual
HR-HPV types were similar to those found during primary
screening in a Swedish multicentre study comprising 5696 women
aged 32–38 years (Swedescreen) (Naucler et al, 2007). The
Swedescreen group found that HPV16, 31, and 33 represented
the highest population-attributable risk proportion in the devel-
opment of CIN2þ. Human papillomavirus type 18 was only the
sixth most commonly identified HR-HPV type resulting in
CIN2þ. Worldwide, HPV33 is associated with the third highest
odds ratio (OR 373.5) for squamous-cell cervical cancer, behind
HPV16 (OR 434.5) and HPV59 (OR 419.5) (Munoz et al, 2003).
Considering that odds ratios vary for different HPV types,
genotyping is needed to estimate risk in the individual case as
well as to plan clinical follow-up and vaccination strategy. We
think our data support the statement of Cuschieri et al (2004) that
‘a broad spectrum test should be implemented until the true
impact of the persistence of less common HR-HPV types in
neoplastic progression is established’.
Minor cytological abnormalities associated with certain HPV
genotypes may progress to cervical cancer. High-risk human
papillomavirus prevalence is similar among women with ASCUS
and LSIL after the age of 30 years, supporting an age limit of
30 years or even younger for triage testing in LSIL cases and no
age limit in ASCUS cases, in order to improve the effectiveness of
the screening programme. Human papillomavirus genotyping
in longitudinal studies is needed to elucidate the importance
of multiple infections for cancer progression, as well as cross-
protection from vaccination.
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